NeuroSense Therapeutics Ltd. NRSNW

Annual Quarterly

No annual revenue total was found in NeuroSense Therapeutics Ltd.'s SEC filings.

NeuroSense Therapeutics Ltd. (NRSN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.7 million. As of Dec 31, 2025 it held $166,000 in cash and investments and $170,000 in total debt.

Revenue
—
Net income
$-11.12M
-9.0% vs prior year
Operating cash flow
$-7.67M
+24.3% vs prior year
Free cash flow
$-7.68M
+24.3% vs prior year
EPS
$-0.44
+18.5% vs prior year
Dividend per share
None
Shares outstanding
32.56M
+40.2% vs prior year
Net cash
$-4,000
FY 2025
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRSN (Nasdaq), NRSNW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Herzliya, Israel
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1875091

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating income
-$11.1M
-$9.9M
Net income
-$11.1M
-$10.2M
Diluted EPS
-$0.44
-$0.54
Operating cash flow
-$7.7M
-$10.1M
Free cash flow
-$7.7M
-$10.1M
Total assets
$1.0M
$4.6M
Total liabilities
$2.6M
$2.0M
Stockholders' equity
-$1.6M
$2.6M
Cash and investments
$166,000
$3.4M
Total debt
$170,000
$73,000

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Nov 2, 2026 Nov 2, 2026
6-K Current report (foreign issuer) Oct 26, 2026 Oct 26, 2026
6-K Current report (foreign issuer) Oct 19, 2026 Oct 19, 2026
6-K Current report (foreign issuer) Oct 13, 2026 Oct 13, 2026
6-K Current report (foreign issuer) Oct 2, 2026 Oct 2, 2026
6-K Current report (foreign issuer) Sep 25, 2026 Jun 30, 2026

All 314 NeuroSense Therapeutics Ltd. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.